Enzyme-Cleavable Prodrug Compositions and Controlled Release Nafamostat Methods
Summary
USPTO granted patent US12599578B2 to Ensysce Biosciences Inc. for pharmaceutical compositions including enzyme-cleavable prodrugs providing enzymatically-controlled release of active agents, combined with controlled release nafamostat. The patent covers 12 claims and methods of use for these pharmaceutical compositions.
What changed
USPTO issued patent US12599578B2 to Ensysce Biosciences Inc. covering pharmaceutical compositions that combine enzyme-cleavable prodrugs with controlled release nafamostat. The invention provides for enzymatically-controlled release of active agents and applies to A61K pharmaceutical compositions.
For pharmaceutical companies and drug developers, this patent establishes IP protection for prodrug delivery technologies. The grant may affect freedom-to-operate analyses for competing formulations involving nafamostat or similar controlled release mechanisms.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
Grant US12599578B2 Kind: B2 Apr 14, 2026
Assignee
Ensysce Biosciences Inc.
Inventors
Lynn Kirkpatrick
Abstract
Aspects of the present disclosure include pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions include an active agent prodrug that provides enzymatically-controlled release of an active agent, and controlled release nafamostat or a pharmaceutically acceptable salt thereof.
CPC Classifications
A61K 31/155 A61K 47/65 A61K 47/64 A61K 9/1623 A61K 9/1635 A61K 9/1652 A61K 38/07 A61K 47/32 A61K 47/38
Filing Date
2022-03-08
Application No.
17689271
Claims
12
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.